ArticleFrontiers in immunology2025
N-glycosylation patterns of plasma immunoglobulin G in anti-synthetase syndrome disease.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Glycoproteomic Signatures of IgG SubclassMedComm · 2026Article
- IgG subclass-specific N-glycosylation differentiates HRCT subtypes in idiopathic inflammatory myopathies-associated ILD.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Anti-synthetase syndrome (ASS) is a subtype of idiopathic inflammatory myopathy (IIM) characterized by characteristic rash, myositis, and interstitial lung disease (ILD). The etiology of ASS is unknown, and patients have a poor quality of life and are prone to pulmonary infection. Recent studies have elucidated the potential role of abnormal glycosylation of immunoglobulin G (IgG) in the pathogenesis of autoimmune diseases. However, the pattern of patient-specific IgG N-glycosylation in ASS has not been fully elucidated. Methods: the GlycoQuant method was used to quantify the intact N-glycopeptides of IgG from 30 ASS patients and 30 healthy controls (HCs). Results and Discussion: Thirteen differentially expressed intact N-glycopeptides were identified (p<0.05). Notably, we observed increased fucosylation (p<0.0001) and decreased N-acetylneuraminic acid (p<0.05) in ASS patients. In addition, specific glycosylation patterns correlated with lung function parameters. Our study revealed the IgG glycosylation profile in ASS patients and provided a valuable reference for further investigation of its potential diagnostic and prognostic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.